As a variety of endocrine therapy drugs, such as tamoxifen, fulvestrant, and aromatase inhibitors (AIs), have shown significant efficacy in patients with ER+ breast cancer, the advantages of low toxicity and high tolerance of endocrine therapy have received extensive attention. This evidence concerns the gene CYP19A1 and breast cancer.